安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Lepodisiran — A Long-Duration Small Interfering RNA Targeting . . .
Elevated lipoprotein (a) concentrations are associated with atherosclerotic cardiovascular disease The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting
- Lepodisiran - Wikipedia
Lepodisiran (LY3819469) is a small interfering RNA that was developed to reduce lipoprotein (a) in people at risk of cardiovascular disease It was developed by Eli Lilly and Company [1][2]
- One dose of experimental therapy reduced lipoprotein(a) more than 94% . . .
The medication, lepodisiran, is a small interfering RNA that reduces the production of Lp (a) in the liver by disabling messenger RNA that is involved in producing apolipoprotein (a), a key component in the Lp (a) particle
- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting . . .
Lepodisiran, like other short interfering RNA and antisense oligonucleotide–based therapies under development for lipoprotein (a) lowering, concentrates the therapeutic agent in hepatocytes by conjugation with N-acetyl-galactosamine, a ligand for hepatic asialoglycoprotein receptors
- Lepodisiran: A new cholesterol drug raising big questions
Explore physician reactions to Lepodisiran, an RNA-based cholesterol drug showing a 94% reduction in Lp (a) Physicians highlight key safety and efficacy concerns
- Single Dose of Lepodisiran Shows Promise in Lowering Lp(a) Over an . . .
A single subcutaneous injection of lepodisiran, an siRNA targeting mRNA for the LPA gene, substantially lowered lipoprotein (a), or Lp (a), below baseline levels for 48 weeks, according to new late-breaking science presented Nov 12 at AHA 2023 and simultaneously published in JAMA
- Novel siRNA Reduces Lipoprotein(a) by More Than 90% for 48 Weeks
A novel short-interfering RNA (siRNA) therapy known as lepodisiran reduced levels of lipoprotein (a) (Lp (a)) below the lowest limit of quantitation for nearly nine months in a first-in-human phase 1 trial
- AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year
A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein (a) – a risk factor for cardiovascular disease – by up to
|
|
|